71573-93-8Relevant academic research and scientific papers
Palladium-Catalyzed Carbonylative Coupling of Aryl Iodides with Alkenylaluminum Reagents
Chen, Bo,Wu, Xiao-Feng
supporting information, p. 7624 - 7629 (2019/10/02)
A highly reactive catalytic system for the carbonylative coupling of aryl iodides with alkenylaluminum reagents has been developed. Various β-substituted γ,δ-unsaturated ketones were produced under mild conditions in good to excellent yields even under ppm level of palladium catalyst. Notably, this also represents the first example on carbonylative transformation of alkenylaluminum compounds. Additionally, by the addition of zinc salt, the selectivity of the product can be modified.
Preparation of unsymmetrical ketones from tosylhydrazones and aromatic aldehydes via formyl C-H bond insertion
Allwood, Daniel M.,Blakemore, David C.,Ley, Steven V.
supporting information, p. 3064 - 3067 (2014/06/23)
Preparation of ketones by insertion of diazo compounds into the formyl C-H bond of an aldehyde is an attractive procedure, but use of structurally diverse diazo compounds is hampered by preparation and safety issues. A convenient procedure for the synthesis of unsymmetrical ketones from bench-stable tosylhydrazones and aryl aldehydes is reported. The procedure can be performed in one pot from the parent carbonyl compound and needs only a base, with no additional promoters being required.
A heterogeneous Ru/CeO2 catalyst effective for transfer-allylation from homoallyl alcohols to aldehydes
Miura, Hiroki,Wada, Kenji,Hosokawa, Saburo,Sai, Masahiro,Kondo, Teruyuki,Inoue, Masashi
scheme or table, p. 4112 - 4114 (2009/12/25)
A simple heterogeneous Ru/CeO2 catalyst was found to be effective for transfer-allylation from homoallyl alcohols to aldehydes, followed by isomerization to give the saturated ketones in high yields.
COMPOUND FOR INHIBITING TYROSINE KINASE ACTIVITY OF DDR2 PROTEIN
-
Page/Page column 28-29, (2010/02/14)
A new furopyrimidine compound, their pharmaceutically acceptable salt, and a tyrosine kinase activity inhibitor. The furopyrimidine compound is a compound defined by chemical formula 1, 2, 3 or 4, on their precursor, and can exist as a form of free base or in an acid-addition salt. Since the furopyrimidine compound has an effect of inhibiting activity of DDR2 tyrosine kinase, it can be used in treating illnesses caused by the DDR2 tyrosine kinase activity such as hepatocirrhosis, rheumatoid arthritis or cancer.
A Rearrangement Route to Fenvaleric Acid
Luzzio, Frederick A.,Fitch, Richard W.
, p. 498 - 501 (2007/10/03)
(±)-Fenvaleric acid 2, the key intermediate for the preparation of the pesticide esfenvalerate 1, was prepared by a novel sequence which first involves the Henry reaction of 2-methyl-1-nitropropane and 4-chlorobenzaldehyde. The nitroaldol reaction provided nitroalcohol 5 which was then reduced to the corresponding aminoalcohol 6. Submission of 6 to an aminopinacol rearrangement promoted by nitrous acid deamination then afforded aldehyde 8 through a 1,2-aryl shift. The product fenvaleric aldehyde 8 was then converted to the title compound 2 by a modified Jones oxidation.
Resolution of Secondary α-Ketoalcohols Catalyzed by Lipase and Inversioon of Stereochemistry
Duh, Tsai-Hui,Wang, Yi-Fong,Wu, Ming-Jung
, p. 579 - 584 (2007/10/02)
Several α-ketoalcohols of synthetic value were resolved using lipase as a catalyst.Lipoprotein lipase (LPL) provided the best rate of hydrolysis and kinetic differentiation.One of these optically pure α-ketoalcohol was converted to (S)-ibuprofen in good optical purity.The stereospecific inversion of (R)-alcohol to (S)-alcohol is described.Key Words Enzymatic resolution; α-Ketoalcohol; (S)-Ibuprofen
Process for the preparation of optically active alpha-acrylalkanoic acids and novel intermediates thereof
-
, (2008/06/13)
A new enantioselective process is described for preparing optically active alpha-arylalkanoic acids by: (a) halogenation on the aliphatic carbon atom alpha to the ketal group, of ketals of formula STR1 in which Ar represents an aryl, optionally substituted; R represents a C1 -C4 alkyl; R1 and R2, represents a hydroxy, a O- M+, OR3 or NR4 R5 group; the carbon atoms indicated by an asterisk both simultaneously are in (R) or (S) configuration. This reaction is diastereoselective, so that a mixture of alpha-haloketals is obtained in which one of the two epimers prevails, and generally strongly prevails, over the other. (b) rearrangement of the haloketals of formula STR2 in which X is Cl, Br or I to alpha-arylalkanoic acids in a single stage or in two successive stages, by way of esters of formula STR3 The compounds (A) and (C) are all new compounds. The rearrangement step (b) may be performed under new, inventive conditions. The esters of formula (C) have pharmacological activity analogous to that of the corresponding alpha-arylalkanoic acids.
Intermediates for preparing optically active carboxylic acids
-
, (2008/06/13)
A process is described for preparing optically active alpha-arylalkanoic acids consisting of rearranging an optically active ketal of formula STR1 in which the substituents have the meaning given in the description of the invention.
Process for the preparation of optically active alpha-arylalkanoic acids and novel intermediates thereof
-
, (2008/06/13)
A new enantioselective process is described for preparing optically active alpha-arylalkanoic acids by: (a) halogenation on the aliphatic carbon atom alpha to the ketal group, of ketals of formula STR1 in which Ar represents an aryl, optionally substituted; R represents a C1 -C4 alkyl; R1 and R2, represents a hydroxy, a O- M+, OR3 or NR4 R5 group; the carbon atoms indicated by an asterisk both simultaneously are in (R) or (S) configuration. This reaction is diastereoselective, so that a misture of alpha-haloketals is obtained in which one of the two epimers prevails, and generally strongly prevails, over the other. (b) rearrangement of the haloketals of formula STR2 in which X is Cl, Br or I to alpha-arylalkanoic acids in a single stage or in two successive stages, by way of esters of formula STR3 The compounds (A) and (C) are all new compounds. The rearrangement step (b) may be performed under new, inventive conditions. The esters of formula (C) have pharmacological activity analogous to that of the corresponding alpha-arylalkanoic acids.
